Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.66
DRTX's Cash to Debt is ranked higher than
60% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. DRTX: 1.66 )
DRTX' s 10-Year Cash to Debt Range
Min: 1.66   Max: No Debt
Current: 1.66

Z-Score: 3.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -161.07
DRTX's ROE (%) is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. DRTX: -161.07 )
DRTX' s 10-Year ROE (%) Range
Min: -594.12   Max: -142.55
Current: -161.07

-594.12
-142.55
ROA (%) -62.05
DRTX's ROA (%) is ranked higher than
58% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. DRTX: -62.05 )
DRTX' s 10-Year ROA (%) Range
Min: -98.24   Max: -62.05
Current: -62.05

-98.24
-62.05
ROC (Joel Greenblatt) (%) -6351.39
DRTX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. DRTX: -6351.39 )
DRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6379.2   Max: -6351.39
Current: -6351.39

-6379.2
-6351.39
» DRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DRTX Guru Trades in

DRTX Guru Trades in

DRTX Guru Trades in

Q1 2014

DRTX Guru Trades in Q1 2014

Jim Simons 60,300 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with DRTX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 17.60
DRTX's P/B is ranked higher than
57% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. DRTX: 17.60 )
DRTX' s 10-Year P/B Range
Min: 0   Max: 24.4
Current: 17.6

0
24.4
EV-to-EBIT -5.97
DRTX's EV-to-EBIT is ranked higher than
51% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DRTX: -5.97 )
DRTX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.97

Current Ratio 3.50
DRTX's Current Ratio is ranked higher than
70% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. DRTX: 3.50 )
DRTX' s 10-Year Current Ratio Range
Min: 0.65   Max: 5.88
Current: 3.5

0.65
5.88
Quick Ratio 3.50
DRTX's Quick Ratio is ranked higher than
72% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. DRTX: 3.50 )
DRTX' s 10-Year Quick Ratio Range
Min: 0.65   Max: 5.88
Current: 3.5

0.65
5.88

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 25.10
DRTX's Price/Tangible Book is ranked higher than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. DRTX: 25.10 )
DRTX' s 10-Year Price/Tangible Book Range
Min: 3.26   Max: 26.4
Current: 25.1

3.26
26.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:DTA.Germany
Durata Therapeutics Inc is a clinical development stage biopharmaceutical company. The Company develops and commercializes novel therapeutics for patients with infectious diseases and acute illnesses.
» More Articles for DRTX

Headlines

Articles On GuruFocus.com
Ttreatment for skin Aug 05 2012 

More From Other Websites
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM) Jul 18 2014
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM) Jul 18 2014
FDA approves Cubist antibiotic for skin infections Jun 20 2014
Coverage initiated on Durata Therapeutics by Gabelli & Co Jun 20 2014
Durata Therapeutics to Present at Upcoming Investor Conferences Jun 17 2014
Durata Therapeutics CEO buys 3,000 shares Jun 13 2014
Durata Therapeutics CEO buys 3,00 shares Jun 13 2014
New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program Jun 04 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 02 2014
Orexigen Will Run: Here's Why May 27 2014
Durata Therapeutics' Skin Drug Gets FDA Nod May 27 2014
High option volume stocks: May 27 2014
Durata Therapeutics falls 12.1% May 27 2014
Durata can carve out lucrative niche with Dalvance, says Janney Capital May 27 2014
Durata Therapeutics falls 7.6% May 27 2014
Durata Therapeutics confirms FDA approval of Dalvance May 23 2014
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin... May 23 2014
[$$] FDA Approves Durata's Dalvance May 23 2014
FDA approves Dalvance to treat skin infections May 23 2014
Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single... Apr 24 2014
Durata Therapeutics to Present at Upcoming Investor Conferences Mar 17 2014
Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014 Mar 17 2014
Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results Mar 17 2014
Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference Feb 18 2014
European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin Dec 23 2013
Durata Therapeutics Submits Marketing Authorization Application for Dalbavancin Dec 03 2013
Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance(TM)... Nov 26 2013
Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference Nov 15 2013
PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics Nov 06 2013
Durata Therapeutics to Present at the 2013 Credit Suisse Healthcare Conference Nov 06 2013
Durata Therapeutics, Inc. Reports Third Quarter 2013 Financial Results Nov 06 2013
Durata Therapeutics to Announce Third Quarter 2013 Financial Results on November 6, 2013 Nov 03 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide